Jennison Associates
IBRX icon

Jennison Associates’s ImmunityBio IBRX Stock Holding History

Jennison Associates’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-100,253
Closed -$1.15M – 699
2015
Q3 		$1.15M Buy
+100,253
New +$2.19M ﹤0.01% 623

Other funds holding IBRX

WCM
Wildcat Capital Management New York $106M AUM 0.1% 1-Year Est. Return
CC
Callan Capital La Jolla, California $1.35B AUM 8.35% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
RIM
RS Investment Management San Francisco, California $9.73B AUM 3.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Jennison Associates's IBRX Position: Q4 2015 in Review

Jennison Associates sold out of ImmunityBio (IBRX) in Q4 2015, closing a stake of 100,253 shares — an estimated $1.15M sold.

Jennison Associates first reported a position in IBRX in Q3 2015 and held it in 1 quarter. The position peaked at $1.15M in Q3 2015. 61 funds tracked by Wall St. Rank hold IBRX as of Q4 2015.

  • Jennison Associates reported no remaining ImmunityBio position as of Q4 2015 after selling out during the quarter.
  • Jennison Associates sold 100,253 ImmunityBio shares in Q4 2015, an estimated $1.15M.
  • Jennison Associates first reported a position in ImmunityBio in Q3 2015 and held it in 1 quarter.
  • Jennison Associates's ImmunityBio position peaked at $1.15M in Q3 2015.
  • 61 funds tracked by Wall St. Rank held ImmunityBio as of Q4 2015.

Based on Jennison Associates's 13F filing for Q4 2015, filed 10 Feb 2016.